Madrigal's stock soars on promising PhII data in NASH, but questions linger
The stock is flying for Madrigal Pharmaceuticals following news that its fatty liver disease drug successfully pared down liver fat in Phase II trials. Shares jumped more than 100% Wednesday morning as the Philadelphia company preps to compete with titans in the space.
Madrigal $MDGL, which merged with cancer drug maker Synta Pharmaceuticals last year, is developing small molecule drugs in cardiovascular-metabolic diseases and the hot (and increasingly crowded) field of non-alcoholic steatohepatitis (NASH).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.